{"id":4342,"date":"2026-11-15T09:00:00","date_gmt":"2026-11-15T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4342"},"modified":"2026-11-17T20:41:53","modified_gmt":"2026-11-18T00:41:53","slug":"jw-discloses-carteyva-reimbursement-price","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4342","title":{"rendered":"JW Discloses CARTEYVA Reimbursement Price"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_JW_Therapeutics_Carteyva_Therapeutic_Indications-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4353\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_JW_Therapeutics_Carteyva_Therapeutic_Indications-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_JW_Therapeutics_Carteyva_Therapeutic_Indications-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_JW_Therapeutics_Carteyva_Therapeutic_Indications-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_JW_Therapeutics_Carteyva_Therapeutic_Indications-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261116_JW_Therapeutics_Carteyva_Therapeutic_Indications.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>JW Therapeutics<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>National Reimbursement Drug List price disclosure (HKEX)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Autologous CD19 CAR T<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>CARTEYVA (relmacabtagene autoleucel)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>CD19<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Large B-cell, follicular and mantle cell lymphoma<\/p>\n<h4>Summary<\/h4>\n<p>JW Therapeutics disclosed a RMB288,600 National Reimbursement Drug List price for relmacabtagene autoleucel, effective 1 January 2027, covering three lymphoma indications. This product-level price is new information beyond China\u2019s 14 November list announcement. Access expansion and margin effects cannot be assumed from the price alone.<\/p>\n<p>The 15 November HKEX-filed investor presentation identifies CARTEYVA as the only CAR-T in the basic list, covering later-line large B-cell, follicular and mantle cell lymphoma. JW reports over 1,200 patients treated, more than 200 certified centers and above 99% first-pass manufacturing success. Its statement that unit cost could fall over 65% versus 2025 actuals depends on introducing new materials and is a projection, not an achieved figure.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> a known national payment price may make referrals and hospital budgeting more predictable, potentially raising use in underpenetrated lymphoma populations. A national listing and existing center network support that pathway. Counterpoint: copay, local reimbursement, eligibility, patient fitness and manufacturing slots still constrain access.<\/p>\n<p><strong>Interpretation B:<\/strong> the negotiated price could compress unit economics even as volume rises. The lower list price supports concern, but net revenue, cost per batch and the conditional cost-saving plan are undisclosed. The three indications have different evidence bases and patient numbers. Claims of China-to-global generalizability require comparator, population and care-infrastructure analysis, not just treatment counts.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>CARTEYVA (relma-cel) is an autologous CD19-directed CAR-T therapy for B-cell lymphomas. Patient T cells are collected, engineered, expanded and reinfused; durable activity depends on product fitness, patient biology and access to certified treatment centers.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Primary HKEX filing verified.<\/li>\n<li>Company-reported manufacturing and market estimates are not independently audited here.<\/li>\n<li>Missing: pre-negotiation net price, provincial rollout, actual 2027 volume and realized unit cost.<\/li>\n<li>Upgrade: rising treated patients with maintained quality and sustainable unit economics; downgrade: coverage without uptake or worsening delivery failures.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The exact payment price makes the earlier policy signal more actionable, but its commercial direction remains mixed until real utilization and costs are observed.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 5 of 5. Signal Direction: mixed. Confidence in Facts: high. Confidence in Interpretation: moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>JW Therapeutics disclosed a RMB288,600 National Reimbursement Drug List price for relmacabtagene autoleucel, effective 1 January 2027, covering three lymphoma indications. This product-level price is new information beyond China\u2019s 14 November list announcement. Access&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4353,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1502,1500,1501],"class_list":["post-4342","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-china-nrdl","tag-jw-therapeutics","tag-relmacabtagene-autoleucel"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4342"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4342\/revisions"}],"predecessor-version":[{"id":4358,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4342\/revisions\/4358"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4353"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4342"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4342"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}